The acquisition agreement comes exactly two years after the two companies began a wide-ranging alliance focused on developing RNA interference drug for metabolic disorders. The most advanced therapy from that alliance is on track to reach the clinic in 2022.
Wondering where the venture capital funding has gone in the healthcare industry? According to CB Insights, it’s the following 10 cities–for Q3 ’13 at least. (Listed in order of amounts of deals; note that though San Francisco saw more deals, San Diego saw more funding.) San Francisco, Calif.: 7 deals, $77 million San Diego, Calif.: […]
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.